Kidney Cancer | Tumor

CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer.

Educated Patient® Kidney Cancer Summit Genetic Testing in RCC Presentation: April 9, 2022

April 20th 2022

Watch Dr. Rana R. McKay, from the University of California San Diego, discuss genetic testing in renal cell carcinoma during the CURE Educated Patient Kidney Cancer Summit.

Clinical Trials Come to a ‘Disappointing’ End When Drug Combo Fails to Improve Outcomes in Kidney and Bladder Cancer

April 19th 2022

The clinical development of BEMPEG plus Opdivo will end after clinical trials showed that the drug combination did not lead to significant improvements in outcomes in patients with kidney or bladder cancer.

Lenvatinib + Pembrolizumab for the Treatment of Metastatic Clear Cell RCC

April 19th 2022

A review of clinical trial data on combination treatments for clear cell renal cell carcinoma.

A Patient’s Perspective on Choosing Systemic Therapy for Metastatic RCC

April 19th 2022

Patients with clear cell renal cell carcinoma speak to their experiences with systemic treatments.

Educated Patient® Kidney Cancer Summit Staging Presentation: April 9, 2022

April 19th 2022

Watch Dr. Vitaly Margulis, from UT Southwestern Medical Center, discuss staging, during the CURE Educated Patient Kidney Cancer Summit.

‘Today Show’ Anchor Hoda Kotb Discusses Fertility Issues Following Cancer Diagnosis, Pfizer Pulls Blood Pressure Drugs Due to Cancer Concerns and More

March 25th 2022

From Pfizer issuing a voluntary recall of three blood pressure drugs due to a high level of a cancer-causing chemical to “Today Show” co-ancho Hoda Kotb discussing her struggles with fertility after receiving a diagnosis of breast cancer, here’s what’s happening in the cancer space this week.

Novel Drug-Keytruda Combo Meets Goal for Kidney Cancer Outcomes Before Trial Enrollment Ends

March 24th 2022

MRX0518 plus Keytruda led to a clinical benefit in four out of 16 evaluable patients with renal cell carcinoma. The drug duo will continue to be studied for multiple types of solid tumors.

A Patient With Stage 4 Cancer Turned to a Life of Advocacy to Help Others Facing ‘Insurmountable’ Obstacles

March 17th 2022

One patient with stage 4 kidney cancer pivoted from being a journalist to a patient advocate, educating patients and others about a cancer that requires more awareness and research funding.

On Kidney Cancer Advocacy: ‘There’s Only One Way to Go, and That’s Forward’

March 3rd 2022

If an oncologist was apprehensive about Steven Edwards getting a second opinion, that might not be the right doctor for him, the kidney cancer survivor said.

Drug Duo Sparks Encouraging Outcomes in Treatment of Clear Cell Kidney Cancer

March 1st 2022

In a recent clinical trial, treatment with Bavencio plus Inlyta produced promising outcomes in the presurgical treatment of patients with non-metastatic, clear cell renal cell carcinoma.

Cabometyx Before Surgery May Shrink Tumors With No Disease Progression in Advanced Kidney Cancer

February 22nd 2022

Treatment with Cabometyx before surgery in patients with advanced renal cell carcinoma, a type of kidney cancer, may provide benefits, although further research is required before a decision is made about its role in presurgical treatment.

Updated Results on Lenvima-Keytruda Combo ‘Still Encouraging’ for Patients With Advanced Kidney Cancer, Expert Says

February 22nd 2022

Although the data failed to identify a predictive biomarker in patients with advanced kidney cancer, an expert from Memorial Sloan Kettering Cancer Center in New York notes that the results indicate that no one should be excluded from receiving Lenvima plus Keytruda.

Fotivda Boosts Survival and Has ‘Interesting’ – and Tolerable – Safety Profile for Kidney Cancer Treatment

February 21st 2022

Fotivda – a TKI drug that was approved last year – not only improved survival outcomes, but was also very tolerable in terms of side effects for patients with metastatic renal cell carcinoma.

Patients With Kidney Cancer ‘Continue to See Benefit’ With Post-Surgical Keytruda

February 16th 2022

At a 30-month follow-up, patients with renal cell carcinoma — which is the most common type of kidney cancer — who underwent nephrectomy continued to benefit from Keytruda after the surgical removal of the affected kidney.

Combination Therapy for Advanced Kidney Cancer Subtype May Lead Patients to Live Longer, Better Lives

January 27th 2022

Opdivo plus Cabometyx prolonged survival with minimal effects to their health status, which may highlight the need for patients to advocate for their quality of life when making treatment decisions.

VHL-Related Kidney Cancer Survivor Reflects on Decades of Change for the Rare Condition

January 24th 2022

When Joseph Heisler was diagnosed with von Hippel-Lindau disease 30 years ago, there was hardly any information on the condition. Fast forward three decades, there is an FDA-approved drug and a handbook of information available in two languages.

Trial to Assess Dose Escalation of Experimental Drug Plus Immunotherapy in Solid Tumors Begins

January 18th 2022

The STELLAR-002 trial is currently underway to examine the combination of XL092, an experimental tyrosine kinase inhibitor, in combination with immuno-oncology therapies for patients with advanced solid tumors.

Welireg May Promote Strong Clinical Activity in VHL-Associated Kidney Cancer With Mild Side Effects

December 30th 2021

As the standard treatment for patients with renal cell carcinoma, the most common type of kidney cancer, related to VHL disease is often surgical procedures, the use of Welireg may reduce surgical burden in patients.

Immunotherapy Use Increased in Patients Ineligible for Cancer Trials, Highlighting the Need for More Research in Vulnerable Populations

December 28th 2021

The use of immunotherapy in patients with advanced cancers and decreased fitness levels or organ function increased from 2014 to 2019, although trials for this treatment typically exclude this population.

Cancer Drug Approvals from 2021 That Patients May Have Missed

December 28th 2021

2021 was full of research advancements and FDA drug approvals that continue to improve cancer care for patients with a variety of malignancies.

Top 5 Kidney Cancer Articles From 2021

December 21st 2021

Take a look back at some of the major milestones in kidney cancer that were achieved in 2021.

Keytruda May Increase Amount of Patients ‘Who May Be Cured’ of Kidney Cancer, But Expert Notes Questions Remain

December 16th 2021

Although the recent FDA approval of Keytruda was exciting for high-risk, nonmetastatic renal cell carcinoma, an expert from The University of MD Anderson Cancer Center notes more work is needed, particularly when it comes to individualizing treatment.

Combination Immunotherapy Helps Patients With Kidney Cancer Live Longer and ‘Get Back to Their Regular Lives’

December 6th 2021

Treatment-free survival with Opdivo and Yervoy was more than twice as long when compared with Sutent alone in patients with kidney cancer.

Radiation Therapy May Give Patients With Kidney Cancer Subtype a ‘Level of Comfort’

November 22nd 2021

Radiation therapy in place of systemic therapy may improve quality of life and treatment costs for patients with renal cell carcinoma.

Expert Discusses Balancing the Surgical Risk for Small Kidney Tumors

November 22nd 2021

Some patients with kidney cancer do not need to rush into the operating room, explained Dr. Alexander Kutikov.

FDA Approves Keytruda for Adjuvant Treatment of Kidney Cancer

November 18th 2021

The approval follows statistically significant improved disease-free survival results.

Emerging Treatments and Future Directions in Metastatic Kidney Cancer

November 10th 2021

From microbiome-based therapies to reinventing an old drug and more, an expert from City of Hope explains the interest around emerging treatment options and approaches in metastatic kidney cancer.

Immunotherapy for Frontline Treatment of Kidney Cancer Has ‘Curative Potential’

November 3rd 2021

An expert discusses how the kidney cancer treatment landscape has changed over the last few years, although the number of options available for patients may make it somewhat confusing to navigate.

Available Treatment Options for von Hippel-Lindau Disease

November 3rd 2021

CURE spoke with Stacy Lloyd, board member of the VHL Alliance, about the treatment options for patients with VHL.

The Basics of von Hippel-Lindau Disease

November 3rd 2021

CURE spoke with Stacy Lloyd, board member of the VHL Alliance, to better understand VHL and its impact on cancer.